Medsamic: Uses, Dosage & Side Effects

What Is Medsamic and What Is It Used For?

Medsamic contains the active ingredient tranexamic acid, a synthetic analogue of the amino acid lysine. Tranexamic acid was first developed in 1962 by Japanese researchers Shosuke and Utako Okamoto at Kobe University, and it has since become one of the most widely used hemostatic agents in modern medicine. The World Health Organization (WHO) includes tranexamic acid on its Model List of Essential Medicines, recognizing it as one of the most effective, safe, and cost-effective medicines needed in a health system. Medsamic is formulated as a sterile solution for intravenous injection at a concentration of 100 mg/mL, making it suitable for use in hospital and emergency settings where rapid hemostatic intervention is required.

The fundamental mechanism of action of tranexamic acid involves the inhibition of fibrinolysis, the physiological process by which the body dissolves blood clots. Under normal circumstances, when a blood vessel is damaged, the coagulation cascade is activated to form a fibrin clot that seals the wound. Simultaneously, the fibrinolytic system begins working to eventually dissolve the clot once the vessel has healed. This process involves the enzyme plasmin, which is formed from its inactive precursor plasminogen. Plasminogen binds to fibrin through lysine-binding sites on its surface, and once bound, it is activated to plasmin by tissue plasminogen activator (tPA). Plasmin then cleaves fibrin into soluble degradation products, dissolving the clot.

Tranexamic acid works by competitively binding to the lysine-binding sites on plasminogen, thereby preventing plasminogen from attaching to fibrin on the surface of the blood clot. Without plasminogen bound to the clot, it cannot be efficiently converted to plasmin, and the clot remains stable for longer. Importantly, tranexamic acid does not promote the formation of new clots; rather, it preserves clots that have already formed. At higher concentrations, tranexamic acid can also directly inhibit plasmin activity. The drug is approximately 6 to 10 times more potent than the older antifibrinolytic agent aminocaproic acid (epsilon-aminocaproic acid), which works through a similar mechanism but with lower binding affinity.

The clinical applications of Medsamic (tranexamic acid injection) are diverse and supported by robust clinical evidence. The most significant evidence comes from two landmark randomized controlled trials that transformed the management of hemorrhage worldwide:

• CRASH-2 Trial (2010): This international, multicenter, randomized, placebo-controlled trial enrolled 20,211 adult trauma patients with significant hemorrhage or at risk of significant hemorrhage across 274 hospitals in 40 countries. Patients who received tranexamic acid (1 g IV over 10 minutes followed by 1 g IV over 8 hours) within 3 hours of injury had a significantly reduced risk of death due to bleeding (4.9% versus 5.7% for placebo; relative risk 0.85). The trial also showed that early administration (within 1 hour) was even more effective, reducing bleeding death by 32%. Crucially, there was no increase in thromboembolic adverse events. This trial led to the widespread adoption of tranexamic acid in trauma protocols globally.
• WOMAN Trial (2017): This randomized, double-blind, placebo-controlled trial enrolled 20,060 women with postpartum hemorrhage across 193 hospitals in 21 countries. Women who received tranexamic acid (1 g IV) within 3 hours of delivery had a significantly reduced risk of death due to bleeding (1.5% versus 1.9% for placebo; relative risk 0.81). There was no increase in thromboembolic events or other adverse outcomes. Based on these results, WHO now recommends tranexamic acid as part of standard treatment for postpartum hemorrhage.

Beyond trauma and obstetric hemorrhage, Medsamic injection is used in numerous other clinical situations. In elective surgery, particularly cardiac surgery, orthopedic procedures (hip and knee replacement), and spinal surgery, prophylactic administration of tranexamic acid has been shown to reduce blood loss by 30-50% and decrease the need for blood transfusions. In dental surgery for patients with hemophilia or other bleeding disorders, tranexamic acid provides effective hemostatic support. It is also used in the management of hereditary angioedema, where it can reduce the frequency and severity of attacks by inhibiting the fibrinolytic system that contributes to increased vascular permeability.

What Should You Know Before Taking Medsamic?

Contraindications

Medsamic injection must not be administered to patients with certain medical conditions where the use of an antifibrinolytic agent could cause serious harm. The most important absolute contraindication is active thromboembolic disease, including deep vein thrombosis (DVT), pulmonary embolism (PE), cerebral thrombosis, or active arterial thromboembolism. Since tranexamic acid inhibits the body's clot-dissolving mechanism, using it in patients with existing pathological blood clots could prevent their natural resolution and potentially lead to life-threatening complications such as stroke or organ infarction.

Patients with a known history of convulsions (seizures) should not receive Medsamic, as tranexamic acid can lower the seizure threshold. This risk is particularly relevant at high doses, as observed in cardiac surgery settings where doses exceeding 100 mg/kg have been associated with an increased incidence of postoperative seizures. The mechanism is thought to involve inhibition of inhibitory glycine receptors and GABA-A receptors in the central nervous system. Subarachnoid hemorrhage is also a contraindication, as antifibrinolytic therapy in this setting has been associated with an increased risk of cerebral vasospasm and delayed cerebral ischemia, potentially worsening outcomes despite reducing rebleeding rates.

Patients with severe renal impairment (creatinine clearance less than 30 mL/min) require dose adjustment rather than complete avoidance, but they must be carefully monitored. Since approximately 95% of tranexamic acid is excreted unchanged by the kidneys, impaired renal function leads to drug accumulation and significantly increased plasma concentrations, raising the risk of adverse effects including seizures and thromboembolic events. Hypersensitivity to tranexamic acid or any of the excipients in the formulation is also an absolute contraindication.

Warnings and Precautions

Several clinical situations require careful risk-benefit assessment before administering Medsamic. Patients with a history of thromboembolic disease (even if not currently active) should be treated with caution, as they may have an underlying predisposition to clot formation that could be exacerbated by antifibrinolytic therapy. In these patients, the clinical benefit of controlling hemorrhage must be weighed against the theoretical risk of promoting thrombus formation or preventing resolution of incidental thrombi. However, it is important to note that the large CRASH-2 and WOMAN trials did not demonstrate an increased risk of thromboembolic events with tranexamic acid use, providing some reassurance.

Disseminated intravascular coagulation (DIC) represents a complex clinical scenario where the use of Medsamic requires particular expertise. In DIC, widespread activation of the coagulation system leads to formation of microthrombi throughout the vasculature, consuming clotting factors and platelets and paradoxically resulting in severe bleeding. In this setting, antifibrinolytic therapy may worsen microvascular thrombosis unless it is combined with appropriate anticoagulation (typically heparin) and replacement of consumed coagulation factors. Only physicians experienced in managing DIC should consider using tranexamic acid in these patients.

Patients with hematuria originating from the upper urinary tract (kidneys or ureters) should be treated with caution. Tranexamic acid can cause clots to form and persist in the renal pelvis or ureters, potentially leading to ureteral obstruction and hydronephrosis. If Medsamic is used in patients with urological bleeding, close monitoring of renal function and urine output is essential, and the potential benefits must clearly outweigh this risk.

Visual disturbances have been reported with long-term use of tranexamic acid, including changes in color vision, visual acuity, and retinal changes. While these are more commonly associated with oral treatment over extended periods, patients receiving repeated or prolonged courses of intravenous tranexamic acid should undergo regular ophthalmological examinations. If visual disturbances develop, the medication should be discontinued and the patient referred for ophthalmological evaluation.

Pregnancy and Breastfeeding

Tranexamic acid crosses the placenta, and while animal reproductive studies have not demonstrated teratogenic effects, the decision to use Medsamic during pregnancy should be based on a careful assessment of risks and benefits. The most important evidence regarding use in pregnancy comes from the WOMAN trial, which specifically evaluated tranexamic acid in women with postpartum hemorrhage. This landmark trial demonstrated that tranexamic acid given within 3 hours of delivery significantly reduces death due to bleeding in women with postpartum hemorrhage, without increasing the risk of thromboembolic events or adverse neonatal outcomes. Based on these findings, WHO now recommends intravenous tranexamic acid (1 g over 10 minutes) as standard treatment for postpartum hemorrhage, to be given as early as possible and within 3 hours of birth.

For indications other than postpartum hemorrhage, the use of Medsamic during pregnancy should be reserved for situations where the benefit clearly outweighs any potential risk, and the decision should be made by a qualified healthcare professional. First-trimester use has limited data, and the theoretical concerns about effects on placental function and fetal development should be considered.

Tranexamic acid is excreted in breast milk, reaching concentrations approximately 1% of the corresponding serum concentration. Given the low transfer to breast milk and the short duration of typical intravenous treatment courses, the risk to breastfed infants is considered very low. The European Medicines Agency (EMA) states that a risk to breastfed newborns/infants cannot be excluded, but that the clinical significance of such low milk concentrations is likely minimal. Breastfeeding women receiving Medsamic should be informed of this and should discuss the risks and benefits with their healthcare provider.

How Does Medsamic Interact with Other Drugs?

The drug interaction profile of tranexamic acid is relatively limited compared to many other medications, primarily because it is not metabolized by the cytochrome P450 enzyme system and is eliminated almost entirely unchanged by renal excretion. However, several clinically important interactions exist that healthcare professionals must be aware of when administering Medsamic. These interactions are primarily pharmacodynamic in nature, meaning they arise from the combined effects of tranexamic acid and other medications on the hemostatic system rather than from changes in drug metabolism or plasma concentrations.

Major Interactions

The most clinically significant interaction is with thrombolytic (fibrinolytic) agents such as alteplase (tPA), tenecteplase, streptokinase, and reteplase. Thrombolytic agents work by activating plasminogen and promoting fibrinolysis to dissolve pathological blood clots in conditions such as acute myocardial infarction, ischemic stroke, and pulmonary embolism. Tranexamic acid has the directly opposite pharmacological effect, inhibiting plasminogen activation and fibrinolysis. Co-administration of these two drug classes would therefore result in mutual antagonism, with each drug counteracting the therapeutic effect of the other. This combination should be avoided unless there is a specific, expert-guided clinical rationale.

Concurrent use of Medsamic with Factor IX complex concentrates (also known as prothrombin complex concentrates, or PCCs) or anti-inhibitor coagulant complexes (such as activated prothrombin complex concentrate, aPCC) carries an increased risk of thromboembolism. Both of these blood products promote coagulation, and when combined with the antifibrinolytic effects of tranexamic acid, the overall thrombotic risk is elevated. If concurrent use is deemed necessary (for example, in hemophilia patients with inhibitors who are bleeding), it should be undertaken with extreme caution and close monitoring for signs of thrombosis.

Minor Interactions

Combined oral contraceptives and other estrogen-containing hormonal therapies increase the baseline risk of venous thromboembolism. While this is not a strict contraindication to tranexamic acid use, the additive effect on thrombotic risk should be considered when making treatment decisions. In practice, short courses of tranexamic acid (such as for surgical bleeding or trauma) are generally acceptable in patients on hormonal contraception, but prolonged concurrent use warrants careful risk assessment.

Tretinoin (all-trans retinoic acid), used in the treatment of acute promyelocytic leukemia, has procoagulant properties that may theoretically compound the risk of thrombosis when used with tranexamic acid. However, patients with acute promyelocytic leukemia frequently have associated DIC and may benefit from antifibrinolytic therapy under specialist supervision.

What Is the Correct Dosage of Medsamic?

Medsamic (tranexamic acid 100 mg/mL) is administered exclusively by the intravenous route, either by slow direct injection or by intravenous infusion. The critical safety requirement for all routes of administration is that the injection must not exceed a rate of 1 mL per minute (100 mg per minute). Rapid intravenous injection of tranexamic acid has been associated with hypotension and, in rare cases, dizziness and visual disturbances. In practical terms, this means that a 1 g dose (10 mL of the 100 mg/mL solution) should be administered over at least 10 minutes. For infusion, the solution may be diluted in compatible intravenous fluids such as 0.9% sodium chloride, Ringer's solution, or 5% glucose solution.

Adults

Children

The safety and efficacy of intravenous tranexamic acid in pediatric patients have been evaluated in several studies, though formal large-scale randomized trials specifically in children are fewer than in adults. The recommended pediatric dose is typically 10–15 mg/kg body weight per dose, administered by slow intravenous injection. This dose may be repeated every 6–8 hours as needed based on clinical response. In pediatric cardiac surgery, a loading dose of 10 mg/kg followed by a continuous infusion of 1 mg/kg/hour has been used. The maximum daily dose should not exceed 60 mg/kg. As in adults, the injection rate must not exceed 100 mg per minute, and the dose should be adjusted for any degree of renal impairment.

Elderly

No specific dose adjustment is required in elderly patients based on age alone. However, since renal function naturally declines with age, many elderly patients will have reduced creatinine clearance that warrants dose adjustment. Before administering Medsamic to elderly patients, renal function should be assessed (ideally using calculated creatinine clearance or estimated glomerular filtration rate) and the dose adjusted accordingly. Elderly patients are also more likely to have cardiovascular comorbidities, a history of thromboembolic disease, or to be receiving anticoagulant or antiplatelet therapy, all of which should be considered when making the decision to use tranexamic acid.

Missed Dose

Medsamic is administered by healthcare professionals in controlled clinical settings (hospitals, operating theaters, emergency departments), so missed doses in the traditional sense are uncommon. If a scheduled dose of a maintenance infusion is delayed, it should be administered as soon as possible unless the next scheduled dose is imminent. The healthcare team should not administer a double dose to compensate for a missed dose. In the context of trauma (CRASH-2 protocol), if the loading dose has been administered but the maintenance infusion is interrupted or delayed, it should be resumed as soon as feasible, as the combined two-dose regimen demonstrated superior outcomes in the trial compared to historical data with single-dose approaches.

Overdose

There is limited clinical data specifically on tranexamic acid overdose by the intravenous route, but the expected consequences are based on the drug's pharmacological profile. Signs and symptoms of overdose may include nausea, vomiting, diarrhea, orthostatic hypotension, dizziness, and headache. The most concerning potential complication of significant overdose is thromboembolic events due to excessive inhibition of fibrinolysis. Seizures have been reported with high doses, particularly in the cardiac surgery setting where doses exceeding 100 mg/kg have been used.

Management of overdose is primarily supportive, as there is no specific antidote for tranexamic acid. Given that 95% of the drug is excreted unchanged in the urine, maintaining adequate renal perfusion and urine output is important. In patients with normal renal function, the drug has a half-life of approximately 2–3 hours, so plasma levels will decrease relatively quickly with supportive care. Hemodialysis may be considered in cases of severe overdose, particularly in patients with impaired renal function, although specific efficacy data for hemodialysis in this context is limited. Patients should be monitored for signs of thrombosis, seizures, and hemodynamic instability.

What Are the Side Effects of Medsamic?

The adverse effect profile of intravenous tranexamic acid has been extensively characterized through clinical trials involving tens of thousands of patients and decades of post-marketing surveillance. In the large CRASH-2 trial (20,211 patients) and WOMAN trial (20,060 patients), tranexamic acid demonstrated a favorable safety profile with adverse event rates similar to placebo for most categories. However, as with all medications, side effects can occur and healthcare professionals should be aware of the full spectrum of potential adverse reactions.

The following classification organizes side effects by frequency according to the internationally accepted MedDRA convention used by the European Medicines Agency (EMA). It is important to note that frequency estimates from clinical trials may differ from post-marketing experience, as post-marketing data captures rarer events in a more diverse patient population over longer time periods.

Gastrointestinal side effects (nausea, vomiting, diarrhea) are the most frequently reported adverse reactions and are generally mild and self-limiting. They appear to be dose-related and more common with higher doses or longer treatment courses. Hypotension is particularly associated with the rate of intravenous administration; adhering to the recommended maximum rate of 100 mg per minute (1 mL per minute) significantly reduces this risk.

The relationship between tranexamic acid and thromboembolic events has been extensively studied. Reassuringly, the CRASH-2 trial did not demonstrate an increase in vascular occlusive events (myocardial infarction, stroke, pulmonary embolism, or deep vein thrombosis) compared with placebo in trauma patients. Similarly, the WOMAN trial showed no increase in thromboembolic events in postpartum women. However, individual case reports and pharmacovigilance data have described thromboembolic events in patients receiving tranexamic acid, particularly when used in combination with other procoagulant agents or in patients with pre-existing risk factors for thrombosis.

Seizures associated with tranexamic acid have been predominantly reported in the cardiac surgery setting, where significantly higher doses (often exceeding 100 mg/kg) were used. A dose-response relationship has been established, with the risk of seizures increasing substantially at doses above the standard therapeutic range. At the doses used in trauma and obstetric hemorrhage (total dose 2 g or less), the seizure risk appears to be very low. The mechanism is thought to involve competitive antagonism of glycine and GABA-A receptors in the central nervous system at high plasma concentrations.

Visual disturbances, including changes in color vision (particularly difficulty distinguishing between red and green), decreased visual acuity, and retinal changes, have been reported primarily with prolonged oral use. However, healthcare professionals should be aware of this potential effect, and patients receiving repeated courses of intravenous tranexamic acid should be monitored for visual symptoms. If visual disturbances develop, the medication should be promptly discontinued and the patient referred for ophthalmological assessment.

How Should You Store Medsamic?

Proper storage of Medsamic injection is essential to maintain the quality, safety, and efficacy of the medication. Tranexamic acid injection solution is a clear, colorless liquid in its intended state. The product should be stored at a temperature not exceeding 25°C (77°F) and protected from direct light. The ampoules should not be frozen, as freezing may affect the integrity of the glass container and the physical properties of the solution. The product should be stored in its original packaging until ready for use to protect it from light exposure.

As a sterile injectable product, Medsamic ampoules are intended for single use only. Once an ampoule has been opened, any unused portion should be discarded immediately. The solution should not be stored or re-used after opening, even if it appears clear and colorless, as the sterility of the product can no longer be guaranteed once the seal has been broken. Before administration, the solution should be visually inspected for particulate matter, discoloration, or any signs of container damage. If the solution appears cloudy, contains visible particles, or is discolored (no longer clear and colorless), it should not be used.

When diluted in compatible intravenous fluids (0.9% sodium chloride, Ringer's solution, or 5% glucose), the diluted solution should be used within 24 hours if stored at 2–8°C (36–46°F), or within 4 hours if stored at room temperature below 25°C. From a microbiological standpoint, the diluted product should ideally be used immediately after preparation. Medsamic injection should not be mixed with blood products, solutions containing penicillin, or solutions with a pH above 8, as incompatibilities may occur. The product should be kept out of the sight and reach of children. Medicines should not be disposed of via wastewater or household waste; healthcare facilities should follow local regulations for the disposal of pharmaceutical waste.

What Does Medsamic Contain?

The active ingredient in Medsamic is tranexamic acid (trans-4-aminomethylcyclohexane-1-carboxylic acid), present at a concentration of 100 mg per milliliter of solution. Tranexamic acid has the molecular formula C₈H₁₅NO₂ and a molecular weight of 157.21 g/mol. It is a white, crystalline powder that is freely soluble in water and practically insoluble in organic solvents such as ethanol and diethyl ether. The chemical structure consists of a cyclohexane ring with an aminomethyl group and a carboxylic acid group in the trans (equatorial) configuration, which gives the molecule its high affinity for the lysine-binding sites on plasminogen.

The excipient in Medsamic injection is water for injections, which serves as the vehicle for dissolving the active ingredient and preparing the sterile solution. The product does not contain preservatives, antimicrobial agents, or buffering salts. The pH of the solution is typically in the range of 6.5–8.0, and the osmolality is approximately 300 mOsm/kg, making it essentially isotonic with blood. This formulation is compatible with most standard intravenous fluids, including 0.9% sodium chloride solution, Ringer's lactate solution, and 5% dextrose (glucose) solution.

Medsamic is supplied in clear glass ampoules, typically available in 5 mL ampoules (containing 500 mg tranexamic acid per ampoule) or 10 mL ampoules (containing 1,000 mg tranexamic acid per ampoule). The glass ampoules comply with pharmacopoeial requirements for parenteral preparations and are designed for single use only. Not all pack sizes may be marketed in every country. Healthcare professionals should verify the specific presentation available in their region and ensure that the correct dose is calculated based on the volume and concentration of the ampoule being used.